In utero gene editing has the potential to prenatally treat genetic diseases that result in significant morbidity and mortality before or shortly after birth. We assessed the viral vector-mediated delivery of CRISPR-Cas9 or base editor 3 in utero, seeking therapeutic modification of Pcsk9 or Hpd in wildtype mice or the murine model of hereditary tyrosinemia type 1, respectively. We observed long-term postnatal persistence of edited cells in both models, with reduction of plasma PCSK9 and cholesterol levels following in utero Pcsk9 targeting and rescue of the lethal phenotype of hereditary tyrosinemia type 1 following in utero Hpd targeting. The results of this proof-ofconcept work demonstrate the possibility of efficiently performing gene editing before birth, pointing to a potential new therapeutic approach for selected congenital genetic disorders.
. This contrasts with the development of antibody and T cell-mediated responses following postnatal gene therapy [1] [2] [3] [4] . The small size of the fetus allows high levels of vectors to be given per fetal weight. Cells of multiple organs are highly proliferative and accessible for efficient vector transduction during fetal development 5 . Finally, in utero editing offers the potential to target genes before disease onset, which is critical for diseases with high prenatal or perinatal morbidity and mortality.
We sought to establish the feasibility of in utero gene editing with Streptococcus pyogenes Cas9 (SpCas9) genome editing or base editor 3 (BE3) base editing 6 . We undertook standard genome editing with adeno-associated viral (AAV) vectors in R26 mTmG/+ mice, which constitutively express red fluorescence in each cell until deletion of a loxP-flanked cassette switches the fluorescence to green. We injected adeno-associated virus serotype 9 (AAV9) encoding Cre recombinase (AAV9-Cre; positive control) or two AAV9 vectors (AAV9-SpCas9-mTmG) encoding SpCas9 and a loxP-targeting guide RNA (gRNA) into embryonic day 16 (E16) R26 mTmG/+ fetuses via the vitelline vein ( Fig. 1a and Supplementary Video 1), providing a first-pass effect to the liver. On day of life 1 (DOL1), we observed editing predominantly in the liver and heart (Supplementary Fig. 1 ).
The ultimate objective of this work was to use BE3 for in utero base editing of hepatocytes. BE3 can make site-specific C→ T or G→ A changes in coding sequences without double-strand DNA breaks, making it potentially safer than standard CRISPR-Cas9 genome editing 7 . The large size of SpCas9-based BE3 (~5.1 kb) preempts its delivery via AAV vectors (capacity of ~4.7 kb). Thus, we turned to adenoviral (Ad) vectors for the subsequent series of proof-of-concept experiments, fully recognizing the limitations of Ad vectors for clinical translation due to adverse host immune responses that might lead to systemic toxicity, including production of proinflammatory cytokines, thrombocytopenia, coagulopathy, and liver damage 8 . We injected E16 wild-type fetuses with an Ad vector expressing green fluorescent protein (Ad-GFP) via the vitelline vein and observed robust hepatocyte transduction at DOL1, with decreased levels at 3 months ( Fig. 1a and Supplementary Fig. 2 ). We then injected Ad vectors encoding either SpCas9 and a loxP-targeting gRNA (Ad-SpCas9-mTmG) or Cre recombinase (Ad-Cre) into E16 R26 mTmG/+ fetuses and observed editing in various organs on DOL1, with the most robust editing seen in the liver and heart (Supplementary Fig. 1 ).
Loss-of-function mutations in PCSK9 reduce cholesterol levels and coronary heart disease risk without serious adverse consequences 9 . Previous studies have demonstrated that CRISPR-Cas9-mediated nonhomologous end joining (NHEJ) or base editing disrupted PCSK9 orthologs in mouse [10] [11] [12] [13] and human hepatocytes 14 in vivo postnatally. We evaluated whether in utero base editing of murine Pcsk9 reduces postnatal plasma PCSK9 and cholesterol levels. We used an Ad vector containing BE3 and a gRNA targeting Pcsk9 codon W159 (Ad-BE3-Pcsk9) that in a previous adult mouse study resulted in conversion to stop codons 12 . Following injection of E16 BALB/c fetuses, Ad-BE3-Pcsk9 resulted in base editing in the liver apparent on DOL1 without evidence of editing in other organs ( Fig. 1b-d) . Analysis of DNA from the organs of the mothers of injected fetuses showed no significant Pcsk9 editing ( Fig. 1e ; nextgeneration sequencing (NGS) on-target Pcsk9 base-edited alleles: 0.06-0.14%, n = 2 mothers; negative control: 0.06-0.3%).
Assessed by Surveyor assays and NGS of the target site, the proportion of Pcsk9 base-edited alleles in the livers of in utero Ad-BE3-Pcsk9-injected mice was stable at 10-15% between DOL1 and 3 months (Fig. 1f,g ). The indel rate was low (~2%) (Fig. 1h) , Letters NaTuRe MedICINe contrasting with > 40% indel rates seen in previous postnatal studies using NHEJ to disrupt Pcsk9 10, 11 . NGS analysis of the nine top predicted off-target sites in liver DNA from two 2-week-old Ad-BE3-Pcsk9-injected mice showed no evidence of editing (Fig. 1i) .
Compared with a control Ad vector, in utero Ad-BE3-Pcsk9 resulted in decreased postnatal levels of PCSK9 protein and total cholesterol at 1 and 3 months, with no differences in alanine transaminase (ALT) levels and grossly normal liver . e, Maternal organ analysis occurred 1 week after fetal injection; three separate liver samples per mother were collected. ctrl Li, liver DNA from injected fetuses (b, n = 3 BE3-Pcsk9, 1 ctrl; c, representative of 4 mice replicates; d, representative of 3 mice replicates; e, representative of 2 mice replicates; f, 2 weeks: n = 3 BE3-Pcsk9, 1 ctrl; 1 month: n = 6 BE3-Pcsk9, 1 ctrl; 3 months: n = 18 BE3-Pcsk9, 2 ctrl). g, NGS of liver DNA in control mice (n = 5) and at DOL1 (n = 4), 2 weeks (n = 3), 1 month (n = 6), and 3 months (n = 18) of age following in utero Ad-BE3-Pcsk9 injection; measure of center, mean. h, Frequencies of base-edited and indel-bearing alleles (liver DNA) in a 3-month-old prenatal recipient of Ad-BE3-Pcsk9. The underlined bases indicate the target codon. i, Base editing and indel rates for the on-target and top nine predicted off-target sites. NGS of liver DNA at 2 weeks of age from two prenatal Ad-BE3-Pcsk9 recipients (results separated by slashes) and a control mouse. The underlined bases indicate the base editing window based on distance from the protospacer adjacent motif (PAM). In cases in which no base editing rates are shown, there were no C bases within the window. Li, liver; Lu, lung; H, heart; B, brain; K, kidney; S, spleen. The arrows indicate the Surveyor cleavage products.
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NaTuRe MedICINe histology ( Fig. 2a-l) . Mice treated postnatally at 5 weeks of age with Ad-BE3-Pcsk9 had substantial editing at early postinjection time points (5 d, 1 month) but attenuated editing at later time points (2 and 3 months) (Fig. 2m,n) . In contrast, prenatal Ad-BE3-Pcsk9 recipients had stable editing over time, with significantly higher editing rates than postnatal recipients at 
NaTuRe MedICINe 3 months, despite having similar rates at 5 d (Fig. 2n) . Previous studies of gene therapy documented immune responses to both the Ad vector and the transgene product following postnatal delivery that were diminished with prenatal delivery 15, 16 . We assessed whether there was a different immune response to the Ad vector and SpCas9-based BE3 transgene product following prenatal versus postnatal Ad-BE3-Pcsk9 delivery, which might explain the difference in editing stability. Serum anti-Ad and anti-SpCas9 antibodies were higher in postnatal compared to prenatal recipients and naive controls at 1 and 3 months postinjection, and equal or lower in prenatal recipients compared to naive controls (Fig. 2o,p) . Liver genomic DNA at DOL1, 1 month, and 3 months of age (Ad-BE3-Hpd DOL1, n = 5; 1 month, n = 9; 3 months, n = 9) or Ad-BE3-Null (ctrl, n = 1). c, The percentage of base-edited Hpd on-target alleles was assessed by NGS of liver genomic DNA in fetal recipients of Ad-BE3-Null (ctrl, n = 3 at DOL1 to 2 weeks of age) and Ad-BE3-Hpd at DOL1 (n = 5), 1 month (n = 9), and 3 months (n = 9). Measure of center, mean. d, Frequencies of base-edited and indel-bearing alleles were assessed at 1 month of age via NGS of liver genomic DNA of prenatal Ad-BE3-Hpd recipients (n = 9). The underlined bases indicate the target codon. e, Genomic DNA isolated from other organs at 1 month of age (2 independent mice as shown) and sperm at 3 months of age (2 independent mice as shown) was assessed by Surveyor assays for Hpd editing following prenatal Ad-BE3-Hpd injection. ctrl, liver DNA from Ad-BE3-Null-injected fetus. f, NGS analysis of the Hpd on-target site and the top ten predicted off-target sites in liver genomic DNA collected at 1 month of age from two Ad-BE3-Hpd recipients and one Ad-BE3-Null (ctrl) recipient. K, kidney; H, heart; Lu, lung; B, brain; O, ovary; T, testis; Li, liver. The arrows indicate the Surveyor cleavage products. Statistical analysis was performed with a Kruskal-Wallis test by ranks.
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Having demonstrated in utero base editing of Pcsk9, we next sought to target a gene for which the in utero approach would be more relevant. Hereditary tyrosinemia type 1 (HT1) results from a mutated Fah gene blocking the tyrosine catabolic pathway 17 . Inhibiting the upstream HPD enzyme in this pathway with the drug nitisinone prevents the accumulation of toxic metabolites and rescues the lethal liver failure (Supplementary Fig. 3 ). We sought to introduce a nonsense mutation in the Hpd gene in utero to permanently knock out gene function. We screened eight gRNAs in vitro and observed the most editing at codon Q352 (Supplementary Fig. 3 ). In utero base editing of Hpd in E16 wild-type fetuses with an Ad vector encoding BE3 and the Q352 gRNA (Ad-BE3-Hpd) resulted in a mean editing rate of ~15% in liver at 2 weeks of age; analysis of other organs showed no editing ( Supplementary Fig. 3) .
Fah -/-mice, a model of HT1, experience neonatal lethality and can be rescued with nitisinone delivered via the mother's breast milk. Previous studies have demonstrated amelioration of HT1 in this model with postnatal gene editing via homology-directed repair or NHEJ [18] [19] [20] . We mated Fah -/-adult mice on nitisinone and administered Ad-BE3-Hpd to E16 fetuses; on DOL1, we placed the recipients with foster mothers not on nitisinone (Fig. 3a) . Base editing in the liver was substantially higher in recipient mice analyzed at 1 and 3 months than at DOL1 (37 and 40% versus 14%) (Fig. 3b,c) , probably due to the survival advantage and subsequent expansion of edited cells [21] [22] [23] . In addition to the desired C→ T nonsense mutation at the target site, there were much lower rates of alternative missense mutations and indels (Fig. 3d) . We observed no evidence of editing in other organs, including gonads, at 1 month (Fig. 3e) ; sperm from two 3-month-old recipient mice with liver Hpd editing rates of 46-57% demonstrated no significant editing by Surveyor assays (Fig. 3e) or NGS (0.2-0.8%; controls: 0.03-0.6%). We observed BE3 expression in the heart (Supplementary Fig. 3 ) and speculate that the Hpd locus was inaccessible to BE3 in cardiomyocytes, where Hpd is not expressed 24 . NGS analysis of the ten top predicted offtarget sites in liver DNA from 1-month-old recipient mice showed no evidence of editing (Fig. 3f) .
In utero Ad-BE3-Hpd treatment rescued the lethal phenotype in Fah -/-mice following withdrawal of nitisinone at birth. In contrast to recipients of the control Ad-BE3-Null vector, all of which lost weight before death and did not survive beyond 21 d, Ad-BE3-Hpd recipients demonstrated appropriate weight gain with 89% survival at 3 months (Fig. 4a,b) . Notably, the weights of Ad-BE3-Hpd-injected mice exceeded those of noninjected Fah -/-mice maintained on nitisinone. Additionally, the liver function of Ad-BE3-Hpd-injected Fah -/-mice and noninjected, nitisinonetreated Fah -/-mice was similar at 1 and 3 months and significantly improved compared to Ad-BE3-Null recipients before their death (Fig. 4c-e and Supplementary Fig. 4 ). Improved survival and liver function in Ad-BE3-Hpd recipients correlated with a substantial reduction in HPD + cells on immunohistochemistry (IHC) at DOL1 ( Supplementary Fig. 4 ) and 1 month (Fig. 4f,g ). Liver histology in 1-month-old Ad-BE3-Hpd recipients revealed no significant inflammation or abnormality; in Ad-BE3-Null-injected mice, variability in nuclear size and apoptotic hepatocytes consistent with liver injury were evident ( Supplementary Fig. 4 ).
In summary, we have established the feasibility of in utero CRISPR-mediated therapeutic editing of metabolic genes. We used Ad vectors for these initial proof-of-concept studies, recognizing that safer alternative methods, such as lipid nanoparticles 13, 25 will need to be explored and optimized for translation to the clinic to occur. This notwithstanding, our work highlights the potential of in utero base editing to target a gene-either by disruption, as done here with Hpd, or potentially by directly correcting disease-causing mutations-for the purpose of treating a congenital genetic disorder that can be diagnosed early in pregnancy 26 . Although HT1 served as a proof-of-concept disease model to investigate in utero -/-mice maintained on nitisinone (n = 33) were serially weighed (a) and followed for survival analysis (b). The weight ratio is represented as mean ± s.e.m. Survival statistical analysis was performed with the log-rank test; *P = 8 × 10
for BE3-Hpd versus BE3-Null. c-e, Serum ALT (c), total bilirubin (d), and aspartate transaminase (AST) (e) levels were assessed at 1 month of age (or just before death in Ad-BE3-Null-injected mice) in Fah -/-mice injected prenatally with Ad-BE3-Hpd (n = 9) or Ad-BE3-Null (n = 8) and taken off nitisinone at DOL1 and in noninjected Fah -/-mice maintained on nitisinone (n = 8). f,g, Livers of Fah -/-mice prenatally injected with Ad-BE3-Hpd and taken off nitisinone at DOL1 (n = 9) and noninjected BALB/c mice (n = 8) were assessed for HPD staining at 1 month of age. Approximately 100,000-300,000 hepatocytes were assessed per sample, and the percentages of HPD − cells were determined. Scale bars, 1 mm (g, left) and 100 μ m (g, right). Measure of center, mean (a,c-f). Statistical analysis was performed with a Kruskal-Wallis test by ranks (c-e) and a two-tailed Mann-Whitney U test (f). 
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Methods
Screening and selection of gRNAs. gRNAs targeting the mouse Pcsk9 and
Hpd genes were screened in vitro in Neuro-2a cells (American Type Culture Collection, ATCC; catalog number: ATCC CCL-131) for base editing activity via Surveyor assays or Sanger sequencing as previously described [10] [11] [12] . Specifically, the protospacer and PAM (5′ -CAGGTTCCATGGGATGCTCT|GGG-3′ ) previously demonstrated to target the mouse Pcsk9 gene at codon W159 were used in the current study 12 . Screening and selection of the gRNAs targeting the mouse Hpd gene involved a similar protocol (the Addgene pCMV-BE3 plasmid was a gift from D. Liu (Broad Institute)). The mouse Hpd sequence was visually inspected, and codons that could be potentially base-edited into nonsense codons were identified. gRNAs were selected if the BE3 PAM sequence (NGG) was 13-17 nucleotides distal to the target cytosine base(s). If base editing resulted in a nonsense codon in an appreciable number of alleles (as indicated by the height of the alternative base peak on Sanger sequencing) the gRNA was designated '+ ' . The protospacer and PAM sequences screened and the corresponding target codon are listed in Supplementary Table 1 . For the R26 mTmG/+ mouse model, gRNAs targeting the loxP sites flanking the mT gene were selected based on their predicted high on-target efficiency and low off-target effects as determined by the online tool CRISPOR (see URLs) 27 . The protospacer and PAM used to target the loxP sites in the current studies was 5′ -ATTATACGAAGTTATATTAA|GGG-3′ .
Generation of adenovirus vectors. The BE3-encoding gene and synthetic polyadenylation sequence from pCMV-BE3, the CAG reporter from pCas9_GFP (Addgene), and the U6 promoter-driven gRNA cassette from pGuide (Addgene) with the protospacer sequence 5′ -CAGGTTCCATGGGATGCTCT-3′ (for Pcsk9 studies), the protospacer sequence 5′ -CATTCAACGTCACAACCACC-3′ (for the Hpd studies), or the protospacer sequence 5′ -GGTGCTAGCCTTGCGTTCCG-3′ (control studies: irrelevant protospacer not matching any sequence in the mouse genome) were cloned into pDUAL-Basic expression vector (Vector Biolabs). For the R26 mTmG/+ experiments, which used SpCas9 and not BE3, the mTmG protospacer (5′ -ATTATACGAAGTTATATTAA-3′ ) was cloned into the Addgene plasmid pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from F. Zhang (Broad Institute)). Vector Biolabs used these constructs to generate recombinant adenovirus type 5 particles. Premade adenovirus type 5 particles containing the GFP transgene or Cre recombinase under a cytomegalovirus promoter were obtained from Vector Biolabs. Ad viral vectors are referred to as Ad-BE3-Pcsk9, Ad-BE3-Hpd, Ad-BE3-Null, Ad-SpCas9-mTmG, Ad-GFP, and Ad-Cre; the titers are indicated in Supplementary Table 2 .
Generation of AAV vectors. AAV9 serotype vectors containing SpCas9 and the gRNA targeting the mTmG protospacer (as cited earlier) were generated by Vector Biolabs. This dual AAV vector system in which two vectors are used to deliver SpCas9 and mTmG gRNA is referred to as AAV9-SpCas9-mTmG. An AAV9 serotype vector containing Cre recombinase (AAV9-Cre) was obtained from the University of Pennsylvania Vector Core. 
Genotyping. FAH mice were genotyped to confirm the Fah
-/-genotype. At weaning or time of euthanasia, 2-mm tail snips were placed in 100 μ l of 1× lysis buffer (50× lysis buffer: 1.25 M NaOH, 10 mM EDTA) and incubated at 95 °C for 1 h; 100 μ l of neutralization buffer (50× neutralization buffer: 2 M Tris-HCl) was then added and samples were vortexed. Extracted DNA was amplified using primers Fah-F (5′ -TCTCCCCCGCACTTAGTTTCC-3′ ) and Fah-R (5′ -GGACTCAGATGCTGGGCTGATG-3′ ), and PCR products were digested with the BsrBI restriction enzyme (New England BioLabs) according to the manufacturer's instructions. Digested samples were run on ethidium bromidestained 1.2% agarose gels for analysis. The mutated Fah allele lacked the BsrBI restriction enzyme site. The genotype was also confirmed with Sanger sequencing.
In utero and postnatal mouse injections. Intravenous in utero injections were performed as previously described 28 ( Supplementary Video 1) . Fetuses of timedated BALB/c, Fah -/-, and R26 mTmG/mTmG × B6 (to generate R26 mTmG/+ fetuses) mice were injected at gestational day 16. Under isoflurane anesthesia and after providing local anesthetic (0.25% bupivacaine subcutaneously), a midline laparotomy was made and the uterine horn exposed. The vitelline vein, which runs along the uterine wall and enters the portal circulation, resulting in first-pass effect to the liver and systemic delivery via the ductus venosus, was identified under a dissecting microscope; 10 μ l of virus (1 × 10 8 to 1 × 10 9 viral particles) was injected per fetus using a 100-μ m beveled glass micropipette. A successful injection was confirmed by temporary clearance of the blood from the vein and absence of extravasation of the injectate. The uterus was then returned to the abdominal cavity and the laparotomy incision was closed in a single layer with 4-0 Vicryl suture. Viral injections into adult mice (BALB/c and B6 mice for Pcsk9 studies) were performed via the retro-orbital vein under isoflurane anesthesia. A total volume of 200 μ l was injected such that ~4 × 10 9 viral particles were injected per mouse.
Screening BALB/c and R26 mTmG/+ animal studies. E16 BALB/c fetuses were injected via the vitelline vein with 1 × 10 8 Ad-GFP particles. The livers of injected mice were assessed on DOL1 and 3 months of age by fluorescence stereomicroscopy and IHC for GFP expression. Similarly, the brain, heart, lung, and kidney of injected mice were assessed for GFP expression on DOL1.
E16 R26 mTmG/+ fetuses were injected via the vitelline vein with 1 × 10 9
Ad-SpCas9-mTmG, 1 × 10 8 Ad-Cre, or 1 × 10 11 AAV9-SpCas9-mTmG particles. Injected mice were killed on DOL1 (5 d postinjection) and the liver, heart, lung, and brain were isolated. A portion of each organ was used to extract genomic DNA using the DNeasy Blood and Tissue Kit (QIAGEN) according to the manufacturer's instructions; the remainder of the organ was used to assess GFP and tdTomato expression by IHC. Genomic DNA was assessed for editing by Sanger sequencing and by PCR analysis using primers (Supplementary Table 3 ) flanking the protospacer sequences within the loxP sites, such that successful editing resulted in amplification of a 545-bp band while unsuccessful editing yielded a 2,951-bp band.
Pcsk9 mouse studies. Prenatal experiments. E16 BALB/c fetuses were injected with 4 × 10 8 Ad-BE3-Pcsk9 or 6 × 10 8 Ad-BE3-Null particles via the vitelline vein. Injected mice were subsequently killed at DOL1, 2 weeks, 1 month, or 3 months of age. Plasma was collected at the time of euthanasia from all mice and at 1 month for mice killed at 3 months of age. Before euthanasia and/or plasma isolation, mice were fasted for 4 h. At the time of euthanasia, genomic DNA was isolated from a portion of liver, heart, lung, brain, kidney, spleen, and ovary for analysis of gene editing by Sanger sequencing, Surveyor assays, and NGS (see the on-target and off-target mutagenesis analyses described later in the text). The remaining liver was fixed in 10% buffered formalin for H&E staining for histologic analysis. Plasma was collected for analysis of PCSK9 protein, total cholesterol, and ALT levels. Whole blood was obtained by retro-orbital bleed and spun at 10,600g for 2 min. Plasma PCSK9 protein and total cholesterol levels were measured using the Mouse Proprotein Convertase9/ PCSK9 Quantikine ELISA Kit (R&D Systems) and the Infinity Cholesterol Reagent (Thermo Fisher Scientific), respectively, according to the manufacturer's instructions. Blood ALT levels were measured using the Infinity ALT/GPT Liquid Stable Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions.
Genomic DNA from the maternal organs of dams whose fetuses underwent prenatal Ad-BE3-Pcsk9 injection were assessed by Surveyor assays and NGS for on-target Pcsk9 editing 1 week after injection. Specifically, DNA from the heart, lung, brain, kidney, ovary, and three distinct liver samples was assessed per mother.
Postnatal experiments. Five-week-old BALB/c or B6 mice were injected with 4 × 10 9
Ad-BE3-Pcsk9 particles via the retro-orbital vein. The liver was harvested at 5 d and 3 months postinjection; genomic DNA was extracted for the analysis of gene editing by Surveyor assays and NGS. In the subset of mice killed at 3 months postinjection, serum was isolated at 1 and 3 months postinjection for analysis of anti-SpCas9 and anti-Ad antibody levels (see later in the text).
Fah
-/-mouse studies. An initial in vivo screening study of the Ad-BE3-Hpd viral vector was performed in time-dated BALB/c fetuses. E16 BALB/c fetuses were injected with 5 × 10 8 Ad-BE3-Hpd particles; the injected fetuses were killed at 2 weeks of age. The liver was harvested for immunohistochemical analysis of HPD staining, and genomic DNA was isolated from the liver, heart, brain, and lung for analysis of gene editing by Sanger sequencing, Surveyor assays, and NGS. For experiments in Fah -/-mice, Fah -/-mice maintained on nitisinone were time-dated; E16 fetuses were injected with 5 × 10 8 Ad-BE3-Hpd or 6 × 10 8 Ad-BE3-Null particles. An additional control group consisting of noninjected Fah -/-mice maintained on nitisinone was included. Injected pups were fostered on DOL1 with BALB/c dams that were not maintained on nitisinone, thus removing nitisinone from the breast milk received by injected pups. All mice were weighed every other day beginning on DOL7, and survival was monitored daily. Liver genomic DNA was assessed for gene editing by Surveyor assays and NGS at DOL1, 1 month, and 3 months of age in recipients of Ad-BE3-Hpd and at ~DOL20 in recipients of Ad-BE3-Null (the time of clinical deterioration). In addition, genomic DNA isolated at 1 month of age from the kidney, heart, lung, brain, and gonads of Ad-BE3-Hpd-injected mice was assessed for gene editing by Surveyor assays. Furthermore, genomic DNA from the sperm of Ad-BE3-Hpd-injected mice was isolated at 3 months of age for on-target editing analysis by NGS. Before euthanasia at 1 month of age for Ad-BE3-Hpd-injected Fah -/-mice and control Fah -/-mice on nitisinone and just before death in the Ad-BE3-Null-injected Fah -/-mice, liver function was assessed by serum biochemical analysis. Specifically, blood was collected by retroorbital bleed, maintained on ice, and immediately centrifuged at 20,800g for 15 min at 4 °C. Total bilirubin, aspartate transaminase, and ALT were measured in fresh serum samples using the Vitros 350 Chemistry Analyzer (Ortho Clinical Diagnostics).
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Histology. At the time of tissue collection, mice were killed by decapitation (DOL1 mice) or CO 2 inhalation (all other mice). Organs were harvested and fixed in 10% buffered formalin or 4% paraformaldehyde. After serial dehydration in ascending concentrations of ethanol and xylene, organs were paraffin-embedded and sectioned. H&E staining was performed for morphologic analysis. IHC was performed to determine the expression of GFP, tdTomato, and the SpCas9-based BE3 using the following antibodies for immunofluorescence images: anti-GFP (goat polyclonal, 1:100; Abcam), RFP (rabbit polyclonal, 1:250; Rockland Immunochemicals), and SpCas9 (mouse, 1:50; Cell Signaling Technology). For GFP analysis by immunoperoxidase staining, slides were initially incubated with anti-GFP (rabbit polyclonal, 1:400; Thermo Fisher Scientific) overnight at 4 °C, washed, and then incubated at room temperature for 30 min with the horseradish peroxidase (HRP) polymer in the SuperPicture Polymer Detection Kit (Thermo Fisher Scientific) and subsequently developed with the DAB Peroxidase (HRP) Substrate Kit (Vector Labs). For HPD analysis, anti-HPD antibody (rabbit polyclonal, 1:1,000; St. John's Laboratory) staining was performed on a BOND-MAX automated staining system (Leica Biosystems). The Bond Refine polymer staining kit (Leica Biosystems) was used. The standard protocol was followed with the exception that primary antibody incubation was extended to 1 h at room temperature and the postprimary step was excluded. Antigen retrieval was performed with Epitope Retrieval Solution 2 BOND (Leica Biosystems) for 20 min. Stained slides were digitally scanned at × 20 magnification on an Aperio CS-O slide scanner (Leica Biosystems).
Liver HPD quantification. Liver HPD expression was quantified by IHC in prenatal recipients of Ad-BE3-Hpd and noninjected, age-matched BALB/c control mice. Following HPD staining and digital slide scanning, whole-slide image analysis using the Aperio ImageScope software (Leica Biosystems) was used to count the total number of cells and the number of HPD − cells in each section as determined through thresholding and area measurement. Between 100,000 and 300,000 cells were counted for each mouse liver sample.
Image analysis. For all histologic analyses except the quantification of HPD expression, images were taken on an Eclipse 80i fluorescence microscope (Nikon). Images for confocal microscopy were taken on an LSM 710 microscope (ZEISS). Fluorescence stereomicroscopy (MZ16 FA fluorescence stereomicroscope, Leica Microsystems) was also used to visualize GFP expression following Ad-GFP and Ad-SpCas9-mTmG injection.
Anti-SpCas9 and anti-Ad serum antibody analysis. The levels of anti-SpCas9 antibodies and presence of anti-Ad antibodies in the serum of mice injected with Ad-BE3-Pcsk9 prenatally were compared to those injected with Ad-BE3-Pcsk9 postnatally and naive, noninjected 1-and 3-month-old BALB/c controls. Serum was isolated at 1 and 3 months after injection, and antibody levels were determined by ELISA as previously described 1, 29 . Briefly, 96-well Nunc MaxiSorp Plates (Thermo Fisher Scientific) were coated with SpCas9 protein (PNA Bio) at 0.5 μ g per well or heat-inactivated (30 min at 90 °C) Ad viral particles (5 × 10 9 particles per well) in 1× coating buffer diluted from Coating Solution Concentrate Kit (KPL) and placed at 4 °C overnight. Plates were washed with 1× wash buffer and blocked with 1% BSA blocking solution (KPL) at room temperature for 1 h. For the anti-SpCas9 studies, serum was diluted 1,000-fold with 1% BSA diluent solution (KPL) and added to wells for 1 h at room temperature with shaking. The mouse monoclonal anti-SpCas9 antibody (clone 7A9; Epigentek) was serially diluted in 1% BSA diluent solution and used as a standard to quantify anti-SpCas9 immunoglobulin G1 levels. For the anti-Ad studies, serum was assessed at three different dilutions secondary to the lack of a standard mouse anti-Ad antibody for quantification. Thus, serum was diluted 1:100, 1:400, and 1:1,600 with 1% BSA diluent solution and added to the wells for 1 h at room temperature with shaking. After the 1-h incubation, wells were washed, and 100 μ l of HRP-labeled mouse immunoglobulin Gκ -binding protein (Santa Cruz Biotechnology) was added to each well for an additional 1 h at room temperature. Wells were subsequently washed 4 times and incubated with 100 μ l of ABTS ELISA HRP Substrate (KPL). The SpectraMax M5 plate reader (Molecular Devices) with the SoftMax Pro 6.3 software was used to measure optical density at 410 nm.
On-target and off-target sequence analysis. On-target editing of the Hpd and Pcsk9 genes was assessed by Surveyor nuclease assays (CEL-I nuclease assays) as previously described 12 . Briefly, genomic DNA from the indicated organs (liver, heart, lung, brain, spleen, kidney, or gonads) was isolated using the DNeasy Blood and Tissue Kit as per the manufacturer's instructions. For sperm DNA isolation, sperm were isolated from within the epididymis and vas deferens, suspended in warm PBS, and centrifuged (20,800 g for 10 min), and the supernatant was discarded. Isolation of DNA from the sperm pellet was then performed with the DNeasy Kit according to the manufacturer's instructions with an additional incubation step (70 °C for 10 min) before adding lysis buffer AL. PCR amplicons (see Supplementary Table 3 for the primers used for the Surveyor assays) were purified using the QIAquick PCR Purification Kit (QIAGEN), analyzed using a Surveyor Mutation Detection Kit (Integrated DNA Technologies) according to the manufacturer's instructions, and run on ethidium bromide-stained 2.5% agarose gels. PCR amplicons of on-and off-target predicted sites for Pcsk9 and Hpd were also subjected to NGS at the Massachusetts General Hospital Center for Computational & Integrative Biology DNA Core (CRISPR Sequencing Service; see URLs). Off-target sites were predicted using CRISPOR (see URLs) 27 , and the top sites as ranked by the mitOfftargetScore were also subjected to NGS. Supplementary Tables 4 and 5 list the predicted Pcsk9 and Hpd off-target sites and the PCR primers used for on-target and off-target NGS analysis.
We determined on-target and off-target base editing proportions and indel proportions as previously described 12 using data from NGS performed at the Massachusetts General Hospital Center for Computational & Integrative Biology DNA Core. In brief, the DNA Core typically obtained at least 50,000 paired-end reads for each PCR amplicon at each target site for each sample. We used custom scripts to map the processed sequencing reads, using the expected PCR amplicon sequence as the reference and discarding the reads that were not successfully mapped. To determine the base editing proportions, since the expected window for base editing spans from positions 4 to 8 in the protospacer, we used a window corresponding to positions 3-9 in the protospacer for each mapped read. In accordance with previously published analyses 30 we discarded a read if the 4 bases proximal to the window (positions − 1 to 2) and 4 bases distal to the window (positions 10-13) did not perfectly match the reference. In each of the remaining reads (denominator), we assessed each of the cytosine bases within the window in the reference for a change to another base; any read with at least one such change was tallied as a base-edited read (numerator).
qRT-PCR. Organ samples stored in RNAlater TissueProtect Tubes (QIAGEN) were used for RNA preparation with the RNeasy Mini Kit (QIAGEN), according to the manufacturer's instructions. Reverse transcription was performed after removal of contaminating genomic DNA, using SuperScript IV VILO Master Mix with ezDNase Enzyme (Thermo Fisher Scientific).
Gene expression was measured using the following TaqMan Gene Expression Assay along with TaqMan Gene Expression Master Mix (Thermo Fisher Scientific): Mouse GAPD (GAPDH) Endogenous Control (VIC/MGB probe, primer limited; Thermo Fisher Scientific), for Gapdh as the reference gene. For the BE3 gene, the primers F: 5′ -AAGCGCATACAACAAGCACA-3′ and R: 5′ -GAATCAGTGTCGCGTCTAGC-3′ were used with SYBR Green (Thermo Fisher Scientific). Each 10 μ l qRT-PCR reaction contained 3 μ l complementary DNA (diluted 1:5 with water) and was performed in technical triplicate. Reactions were carried out on the QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher Scientific). Relative expression levels were quantified by the 2 -ΔΔCt method.
Statistics.
A two-tailed Student's t-test was used for experiments involving the comparison of two groups in which data was normally distributed as determined by the D' Agostino and Pearson omnibus test of normality. The Mann-Whitney U test was used for experiments involving the comparison of two groups in which data was not normally distributed. The Kruskal-Wallis test by ranks for multiple independent samples, using the Dunn test with adjustment of the P value according to the false discovery rate procedure of Benjamini-Hochberg, was used for experiments involving the comparison of more than two experimental groups. Survival statistics were assessed with the log-rank test. Unless otherwise indicated, data are represented as the mean ± s.e.m. or the mean with individual values.
Reporting summary. Additional information on research design is available in the Nature Research Reporting Summary linked to this article.
Code availability. The custom code used to calculate the percent editing of ontarget and off-target sites as determined by NGS has previously been validated 12, 31 and is available from the corresponding authors upon reasonable request.
Data availability
The data that support the findings of this study are available within the paper and its supplementary information files. DNA sequencing data have been deposited on the NCBI Sequence Read Archive under accession SRP155635.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
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Data analysis
We used custom code to determine the on-target and off-target base editing and indel rates reported in this manuscript; use of the code was previously published in refs. 3 and 18. Data analysis was performed with GraphPad Prism Version 6.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available within the paper and its supplementary information files.
